|
Distinction
Patb, until now (per my onc at one point several years ago) the reason I think is that taxanes were considered not to work well in the larger group of those who are HR+, so were used primarily for those in the HR- group. Apparently in looking now, they are seeing what they didn't before -- that in the more limited group of bc that is HER2, those who happen to be HR+ DO benefit. (Which means, you and me at least, and perhaps Barbara too...)
correct me if I am wrong, anyone...
A.A.
|